Treatment of restless legs syndrome: Evidence‐based review and implications for clinical practice (Revised 2017) §

@article{Winkelmann2018TreatmentOR,
  title={Treatment of restless legs syndrome: Evidence‐based review and implications for clinical practice (Revised 2017) §},
  author={Juliane Winkelmann and Richard Allen and Birgit H{\"o}gl and Yuichi Inoue and Wolfgang Hermann Oertel and Aaro V Salminen and John W. Winkelman and Claudia Trenkwalder and Cristina Sampaio},
  journal={Movement Disorders},
  year={2018},
  volume={33}
}
The objective of the current review was to update the previous evidence‐based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise… Expand
Restless Legs Syndrome and Other Movement Disorders of Sleep—Treatment Update
TLDR
With emerging evidence of augmentation being a side effect specific to dopaminergic treatment, gabapentinoids are considered a safer option as initial treatment of restless legs syndrome, and in severe refractory RLS, oxycodone-naloxone can be used. Expand
Comparative efficacy and acceptability of treatments for restless legs syndrome in end-stage renal disease: a systematic review and network meta-analysis.
  • Chien-Wei Huang, Min-Jing Lee, +4 authors P. Lin
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2019
TLDR
This network meta-analysis supports that gabapentin is the most effective treatment for RLS in ESRD patients and exercise plus dopamine agonist is a favorable combination therapy concerning side effects. Expand
The Management of Restless Legs Syndrome: An Updated Algorithm.
TLDR
This work defines refractory RLS and describes management approaches, including combination therapy and the use of high-potency opioids, and discusses the available drugs, the factors determining which to use, and their adverse effects. Expand
Iron supplementation for restless legs syndrome - A systematic review and meta-analysis.
TLDR
The meta-analysis supports the use of iron, oral or IV, as effective therapy for patients with RLS, and suggests subgroups of patients most likely to benefit from iron supplementation should be assessed. Expand
Update on Restless Legs Syndrome: from Mechanisms to Treatment
TLDR
The understanding of disease pathophysiology has improved, specifically regarding iron regulation in the brain and the role of other pathways such as opioid signaling and brain and spinal cord circuitry may play in RLS/WED. Expand
An update on the treatment of Restless Legs Syndrome/Willis-Ekbom Disease: prospects and challenges
TLDR
This review provides an update regarding the treatment of RLS/WED with particular attention to future challenges for its management, and reviewed a large variety of treatments studied in clinical trials and supported by the most updated guidelines. Expand
Challenges in the Treatment of Restless Legs Syndrome: A Case Report
TLDR
This report demonstrates a challenging case of RLS in the setting of psychiatric comorbidities, development of augmentation, and polypharmacy in a 69-year-old Caucasian gentleman with bipolar disorder type I, unspecified anxiety disorder, obstructive sleep apnea, and treatment-refractory RLS. Expand
Therapies for Restless Legs in Parkinson's Disease.
TLDR
The treatment of RLS in PD consists in adaptation of dopaminergic treatment and introduction of alpha-2-delta ligands and, in refractory cases, of opioids or deep brain stimulation. Expand
Botulinum Toxin in Restless Legs Syndrome—A Randomized Double-Blind Placebo-Controlled Crossover Study
TLDR
IncoA injection lead to a reduction in severity of RLS symptoms, pain score, and quality of life, without any adverse effects. Expand
Reply to: A note on rotigotine for restless legs syndrome after renal transplantation
  • A. Salminen, Richard P. Allen, +6 authors J. Winkelmann
  • Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 2019
TLDR
The notion that rotigotine, even at 1-2 mg per day may constitute an efficacious and safe option to treat RLS in RT patients is supported, albeit small, by a retrospectively analyzed 7 female RT patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 89 REFERENCES
Treatment of restless legs syndrome with pregabalin: A double-blind, placebo-controlled study
TLDR
The benefits of pregabalin on sensory and motor symptoms in restless legs syndrome (RLS) and its utilization in health research is overstated because the recommendation of placebo in clinical trials is based on efficacy, shorter study duration, and lower cost. Expand
Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.
TLDR
This study confirms that ropinirole improves RLS symptoms and subjective measures of sleep, quality of life, and anxiety and that it is generally well tolerated. Expand
Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension.
TLDR
In this subset of patients with RLS and a baseline IRLS total score ≥ 24, ropinirole was effective and well tolerated compared with placebo and the adverse event profile was consistent with that reported in previous clinical trials. Expand
Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial.
TLDR
PCDs resulted in clinically significant improvements in symptoms of RLS in comparison to the use of sham devices and may be an effective adjunctive or alternative therapy for RLS. Expand
Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries.
TLDR
Ropinirole improves restless legs syndrome compared with placebo, with benefits apparent by week 1, and is generally well tolerated. Expand
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi‐center, randomized, active controlled trial
TLDR
This first large‐scale double‐blind, randomly assigned study in RLS showed superior efficacy of cabergoline versus levodopa after a 30‐week long‐term therapy and Tolerability was found more favorable withlevodopa than with Cabergoline. Expand
Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double‐blind, placebo‐controlled pilot study
TLDR
This pilot study suggests that continuous delivery of rotigotine by means of a patch may provide an effective and well‐tolerated treatment of RLS symptoms both during night and day. Expand
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial
TLDR
Primary efficacy outcomes were absolute change from baseline to end of maintenance in IRLS sum score and in the clinical global impressions (CGI) item 1 score, assessed by analysis of covariance in the intention-to-treat population. Expand
Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
TLDR
Treatment of existing augmentation should be initiated, where possible, with the elimination/correction of extrinsic exacerbating factors (iron levels, antidepressants, antihistamines, etc.). Expand
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.
TLDR
This dose-finding trial identified the range for a maintenance dose of rotigotine from 1mg/24h to 3mg/ 24h and the CGI and the RLS-6 severity items supported the efficacy of theRotigotine doses beyond 0.5mg/25h. Expand
...
1
2
3
4
5
...